A vectored equine herpesvirus type 1 (EHV-1) vaccine elicits protective immune responses against EHV-1 and H3N8 equine influenza virus

Vaccine

Volumn 28, Issue 4, 2010, Pages 1048-1055

  Van de Walle, Gerlinde R ^a,b   May, Maeva A ^a   Peters, Sarah T ^a   Metzger, Stephan M ^a   Rosas, Cristina T ^a   Osterrieder, Nikolaus ^a,c  

^a Cornell University ^*  (United States)

^b GHENT UNIVERSITY   (Belgium)

^c FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Abortigenic; EHV 1; EIV; MLV

Indexed keywords

EQUINE HERPES VIRUS 1 VACCINE; H3 PROTEIN; HERPES VACCINE; LIVE VACCINE; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; EQUINE ABORTION HERPETOVIRUS; EQUINE HERPES VIRUS; HORSE; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A H3N8; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIREMIA;

ANIMALS; ANTIBODIES, VIRAL; GENETIC VECTORS; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 1, EQUID; HERPESVIRUS VACCINES; HORSE DISEASES; HORSES; INFLUENZA A VIRUS, H3N8 SUBTYPE; INFLUENZA VACCINES; ORTHOMYXOVIRIDAE INFECTIONS; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VIREMIA; VIRUS SHEDDING;

EID: 74149093531     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.10.123     Document Type: Article

References (38)

1. Brosnahan MM, Osterrieder N. Equine herpesvirus-1: a review and update. Equine Vet J 2009; in press.
2. United States Department of Agriculture, Animal and Plant Health Inspection Service (USDA-APHIS). Equine herpesvirus myeloencephalopathy: a potential emerging disease (2007). http://www.aphis.usda.gov/vs/nahss/equine/ehv Available at: http://www.aphis.usda.gov/vs/nahss/equine/ehv
3. Rosas C.T., Goodman L.B., von Einem J., and Osterrieder N. Equine herpesvirus type 1 modified live virus vaccines: quo vaditis?. Expert Rev Vaccines 5 1 (2006) 119-131
4. Patel J.R., and Heldens J. Equine herpesviruses 1 (EHV-1) and 4 (EHV-4)-epidemiology, disease and immunoprophylaxis: a brief review. Vet J 170 1 (2005) 14-23
5. Goodman L.B., Wagner B., Flaminio M.J., Sussman K.H., Metzger S.M., Holland R., et al. Comparison of the efficacy of inactivated combination and modified-live virus vaccines against challenge infection with neuropathogenic equine herpesvirus type 1 (EHV-1). Vaccine 24 17 (2006) 3636-3645
6. Mayr A., and Pette J. 1st experiments concerning the vaccination of horses against rhino-pneumonia (viral abortion of mares) with a live vaccine from cell cultures. Bull Off Int Epizoot 70 1 (1968) 133-140
7. Mayr A., Pette J., Petzoldt K., and Wagener K. Studies on the development of a live vaccine against rhinopneumonitis (mare abortion) of horses. Zentralbl Veterinarmed B 15 3 (1968) 406-418
8. Hubert P.H., Birkenmaier S., Rziha H.J., and Osterrieder N. Alterations in the equine herpesvirus type-1 (EHV-1) strain RacH during attenuation. Zentralbl Veterinarmed B 43 1 (1996) 1-14
9. Neubauer A., Meindl A., and Osterrieder N. Mutations in the US2 and glycoprotein B genes of the equine herpesvirus 1 vaccine strain RacH have no effects on its attenuation. Berl Munch Tierarztl Wochenschr 112 9 (1999) 351-354
10. O'Callaghan D.J., Colle III C.F., Flowers C.C., Smith R.H., Benoit J.N., and Bigger C.A. Identification and initial characterization of the IR6 protein of equine herpesvirus 1. J Virol 68 9 (1994) 5351-5364
11. Osterrieder N., Neubauer A., Brandmuller C., Kaaden O.R., and O'Callaghan D.J. The equine herpesvirus 1 IR6 protein that colocalizes with nuclear lamins is involved in nucleocapsid egress and migrates from cell to cell independently of virus infection. J Virol 72 12 (1998) 9806-9817
12. Osterrieder N., Neubauer A., Brandmuller C., Kaaden O.R., and O'Callaghan D.J. The equine herpesvirus 1 IR6 protein influences virus growth at elevated temperature and is a major determinant of virulence. Virology 226 2 (1996) 243-251
13. Osterrieder N., Holden V.R., Brandmuller C., Neubauer A., Kaaden O.R., and O'Callaghan D.J. The equine herpesvirus 1 IR6 protein is nonessential for virus growth in vitro and modified by serial virus passage in cell culture. Virology 217 2 (1996) 442-451
14. Van de Walle G.R., Goupil R., Wishon C., Damiani A., Perkins G.A., and Osterrieder N. A single-nucleotide polymorphism (SNP) in a herpesvirus DNA polymerase is sufficient to cause lethal neurological disease. J Inf Dis 200 1 (2009) 20-25
15. Rosas C.T., Konig P., Beer M., Dubovi E.J., Tischer B.K., and Osterrieder N. Evaluation of the vaccine potential of an equine herpesvirus type 1 vector expressing bovine viral diarrhea virus structural proteins. J Gen Virol 88 Pt 3 (2007) 748-757
16. Rosas C.T., Tischer B.K., Perkins G.A., Wagner B., Goodman L.B., and Osterrieder N. Live-attenuated recombinant equine herpesvirus type 1 (EHV-1) induces a neutralizing antibody response against West Nile virus (WNV). Virus Res 125 1 (2007) 69-78
17. Rosas C.T., Paessler S., Ni H., and Osterrieder N. Protection of mice by equine herpesvirus type 1 based experimental vaccine against lethal Venezuelan equine encephalitis virus infection in the absence of neutralizing antibodies. Am J Trop Med Hyg 78 1 (2008) 83-92
18. Daly J.M., Newton J.R., and Mumford J.A. Current perspectives on control of equine influenza. Vet Res 35 4 (2004) 411-423
19. Paillot R., Hannant D., Kydd J.H., and Daly J.M. Vaccination against equine influenza: quid novi?. Vaccine 24 19 (2006) 4047-4061
20. Barbic L., Madic J., Turk N., and Daly J. Vaccine failure caused an outbreak of equine influenza in Croatia. Vet Microbiol 133 1-2 (2009) 164-171
21. Bryant N.A., Rash A.S., Russell C.A., Ross J., Cooke A., Bowman S., et al. Antigenic and genetic variations in European and North American equine influenza virus strains (H3N8) isolated from 2006 to 2007. Vet Microbiol 138 1-2 (2009) 41-52
22. World organisation for animal health (OIE). Conclusion and recommendations from the Expert Surveillance Panel on Equine Influenza Vaccines (2006) p. 35-36
23. Tischer B.K., von Einem J., Kaufer B., and Osterrieder N. Two-step red-mediated recombination for versatile high-efficiency markerless DNA manipulation in Escherichia coli. Biotechniques 40 2 (2006) 191-197
24. Rosas C., Van de Walle G.R., Metzger S.M., Loelzer K., Dubovi E.J., Kim S.G., et al. Evaluation of a vectored equine herpesvirus type 1 (EHV-1) vaccine expressing H3 haemagglutinin in the protection of dogs against canine influenza. Vaccine 26 19 (2008) 2335-2343
25. Rudolph J., and Osterrieder N. Equine herpesvirus type 1 devoid of gM and gp2 is severely impaired in virus egress but not direct cell-to-cell spread. Virology 293 2 (2002) 356-367
26. von Einem J., Wellington J., Whalley J.M., Osterrieder K., O'Callaghan D.J., and Osterrieder N. The truncated form of glycoprotein gp2 of equine herpesvirus 1 (EHV-1) vaccine strain KyA is not functionally equivalent to full-length gp2 encoded by EHV-1 wild-type strain RacL11. J Virol 78 6 (2004) 3003-3013
27. Wellington J.E., Allen G.P., Gooley A.A., Love D.N., Packer N.H., Yan J.X., et al. The highly O-glycosylated glycoprotein gp2 of equine herpesvirus 1 is encoded by gene 71. J Virol 70 11 (1996) 8195-8198
28. von Einem J., Smith P.M., Van de Walle G.R., O'Callaghan D.J., and Osterrieder N. In vitro and in vivo characterization of equine herpesvirus type 1 (EHV-1) mutants devoid of the viral chemokine-binding glycoprotein G (gG). Virology 362 1 (2007) 151-162
29. Goodman L.B., Loregian A., Perkins G.A., Nugent J., Buckles E.L., Mercorelli B., et al. A point mutation in a herpesvirus polymerase determines neuropathogenicity. PLoS Pathog 3 11 (2007) e160
30. Dispas M., Schynts F., Lemaire M., Letellier C., Vanopdenbosch E., Thiry E., et al. Isolation of a glycoprotein E-deleted bovine herpesvirus type 1 strain in the field. Vet Rec 153 7 (2003) 209-212
31. Lemaire M., Schynts F., Meyer G., Georgin J.P., Baranowski E., Gabriel A., et al. Latency and reactivation of a glycoprotein E negative bovine herpesvirus type 1 vaccine: influence of virus load and effect of specific maternal antibodies. Vaccine 19 32 (2001) 4795-4804
32. Schild G.C., Oxford J.S., and Virelizier J.L. Immunity to influenza. Dev Biol Stand 28 (1975) 253-272
33. Soboll G., Horohov D.W., Aldridge B.M., Olsen C.W., McGregor M.W., Drape R.J., et al. Regional antibody and cellular immune responses to equine influenza virus infection, and particle mediated DNA vaccination. Vet Immunol Immunopathol 94 1-2 (2003) 47-62
34. Holmes M.A., Townsend H.G., Kohler A.K., Hussey S., Breathnach C., Barnett C., et al. Immune responses to commercial equine vaccines against equine herpesvirus-1, equine influenza virus, eastern equine encephalomyelitis, and tetanus. Vet Immunol Immunopathol 111 1-2 (2006) 67-80
35. Townsend H.G., Penner S.J., Watts T.C., Cook A., Bogdan J., Haines D.M., et al. Efficacy of a cold-adapted, intranasal, equine influenza vaccine: challenge trials. Equine Vet J 33 7 (2001) 637-643
36. Mumford J.A., and Wood J. Establishing an acceptability threshold for equine influenza vaccines. Dev Biol Stand 79 (1992) 137-146
37. Breathnach C.C., Clark H.J., Clark R.C., Olsen C.W., Townsend H.G., and Lunn D.P. Immunization with recombinant modified vaccinia Ankara (rMVA) constructs encoding the HA or NP gene protects ponies from equine influenza virus challenge. Vaccine 24 8 (2006) 1180-1190
38. Nelson K.M., Schram B.R., McGregor M.W., Sheoran A.S., Olsen C.W., and Lunn D.P. Local and systemic isotype-specific antibody responses to equine influenza virus infection versus conventional vaccination. Vaccine 16 13 (1998) 1306-1313